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Background: Cancer cells in the advanced stage show aberrant antioxidant capacity to detoxify excessive ROS
resulting in the compensation for intrinsic oxidative stress and therapeutic resistance. PDAC is one of the most
lethal cancers and often associated with a high accumulation of ROS. Recent studies identified gold(I) NHC
complexes as potent TrxR inhibitors suppressing cell growth in a wide spectrum of human malignant cell lines at
the low micromolar concentration. However, the mechanism of action is not completely elucidated yet.
Methods: To understand the biological function of gold(I) NHC complexes in PDAC, we used a recently published
gold(I) NHC complex, MC3, and evaluated its anti-proliferative effect in four PDAC cell lines, determined by MTT and
SRB assays. In further detailed analysis, we analyzed cellular ROS levels using the ROS indicator DHE and mitochondrial
membrane potential indicated by the dye JC-1 in Panc1. We also analyzed cell cycle arrest and apoptosis by FACS. To
elucidate the role of specific cell signaling pathways in MC3-induced cell death, co-incubation with ROS
scavengers, a p38-MAPK inhibitor and siRNA mediated depletion of ASK1 were performed, and results were
analyzed by immunoblotting, ELISA-microarrays, qRT-PCR and immunoprecipitation.
Results: Our data demonstrate that MC3 efficiently suppressed cell growth, and induced cell cycle arrest and
apoptosis in pancreatic cancer cells, in particular in the gemcitabine-resistant cancer cells Panc1 and ASPC1.
Treatment with MC3 resulted in a substantial alteration of the cellular redox homeostasis leading to increased
ROS levels and a decrease in the mitochondrial membrane potential. ROS scavengers suppressed ROS formation
and rescued cells from damage. On the molecular level, MC3 blocked the interaction of Trx with ASK1 and
subsequently activated p38-associated signaling. Furthermore, inhibition of this pathway by using ASK1 siRNA
or a p38 inhibitor clearly attenuated the effect of MC3 on cell proliferation in Panc1 and ASPC1.
Conclusions: Our results confirm that MC3 is a TrxR inhibitor and show MC3 induced apoptosis in
gemcitabine-resistant PDACs. MC3 mediated cell death could be blocked by using anti-oxidants, ASK1 siRNA or
p38 inhibitor suggesting that the Trx-ASK1-p38 signal cascade played an important role in gold(I) NHC
complexes-mediated cellular damage.
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The discovery of cis-diamminedichloroplatinum (cisplatin)
as an antitumor agent by Rosenberg in 1965 was a hall-
mark in inorganic medicinal chemistry [1]. Although cis-
platin as well as its derivatives, carboplatin and oxaliplatin,
are correlated with high toxicity, limited selectivity and a
high ratio of drug resistance [2,3], they still are widely used
as effective chemotherapeutic substances [4,5]. In the last
three decades several other metal-based compounds were
synthesized with the expectation to overcome therapeutic
limitations, which include ruthenium- [6,7], rhodium- [8],
iridium- [8] and gold-complexes [9,10]. While cisplatin
and its derivatives exert their anti-proliferative activity
through DNA damage [11], and a specific cellular cyto-
toxic response [12], organo-metal complexes can also act
through other mechanisms [13]. For gold-complexes a
strong inhibition of thiol-containing enzymes like Thiore-
doxin Reductase (TrxR) has been demonstrated due to the
high native affinity of gold to thiol-group [9,10].
The rapid proliferation of cancer cells requires high
metabolic activity, which includes increased glycolysis
but also an elevation of other metabolic reactions. Due
to this increase in metabolic rate, cancer cells, in par-
ticular, those in advanced stage are prone to high oxida-
tive stress caused by abundant reactive oxygen species,
considered to mainly originate from electronic leakage
of mitochondrial respiratory complexes [14,15]. Interest-
ingly, a moderated increase in ROS level in cancer cells
is an indicator of DNA damage, genomic instability, pro-
liferation, migration and formation of metastasis, while
cells with an excessive accumulation of ROS will typically
undergo irreversible cell death [16,17]. There are strong
evidences that adaptive mechanisms enable cancer cells to
escape from oxidative damage [18,19] by means of over-
expressing ROS scavengers including Thioredoxin (Trx)
and/or Glutathione (Glu) and pro-survival proteins like
Bcl-xl [20]. Activation of both, redox control and anti-
apoptotic signaling will help cancer cells to cope with le-
thality in response to aberrant ROS levels.
Trx and TrxR provide a coupled redox system, which is
required for redox reactions in biosynthetic pathways and
is involved in the control of redox homeostasis in cells
[19,21]. Trx, a reduction/oxidation protein, can be oxi-
dized, e.g. by abundant ROS, which leads to formation of a
disulfide bridge. The reduction by TrxR re-activates Trx
providing a circuit for sequential turnover in multiple oxi-
dation/reduction cycles [19,21]. In its reduced form Trx
inhibits apoptosis signal-regulating kinase 1 (ASK1) and
the downstream mitogen-activated protein kinase p38
(p38-MAPK). Upon accumulation of ROS, Trx is oxidized
and ASK1 is activated leading to apoptotic cell death
[22,23]. In several cancer cells, over-expression of Trx in-
creases the capacity for ROS, which leads to increased
drug resistance and promotes tumor progression [24].Therefore, several small molecules targeting the Trx-TrxR
system have been developed to preferentially induce cell
death in malignant cells [25-27] due to the increased de-
pendence of these cells on the anti-oxidative activity of the
Trx-TrxR system [28-30].
Recently, we presented several gold(I) N-heterocyclic car-
bene (NHC) complexes as potent inhibitors of TrxR, show-
ing clear and strong anti-proliferative effects on a broad
spectrum of tumor cells [9,10]. In this article, we performed
a more detailed analysis of the underlying molecular mech-
anism leading to cell death and found that [di-(1,3-diethyl-
benzylimidazol-2-ylidene)]gold(I) iodide (called MC3), a
TrxR inhibitor, showed a high anti-proliferative effect on
pancreatic ductal adenocarcinoma (PDAC). This effect was
clearly associated with increased ROS production and acti-
vation of p38-MAPK. ROS scavengers, inhibition of p38
signaling with a specific inhibitor or depletion of ASK1 at-
tenuated MC3-induced apoptosis. In addition, we could
clearly show that treatment with MC3 interrupted binding
of Trx to ASK1. Our findings provide a detailed mechanism
for the activation of ASK1-p38 signaling following interfer-
ence with the Trx-TrxR redox balance as a major mechan-
ism in gold(I) compounds-mediated cell death.
Results
Anti-proliferative effect of MC3 in gemcitabine-resistant
pancreatic cancer cells
Gold(I) NHC complexes had been identified as potent
anti-tumor agents with IC50 value in the low micromo-
lar concentration range in various cancer cell lines,
which represent different tumors including MCF7
(breast cancer), HT29 and HCT116 (colon cancer), and
HepG2 (liver cancer) [9,10]. Here we investigated their
effects on pancreatic cancer cells, one of the most diffi-
cult to treat cancers with only 5% of 5-year survival in
patients [31]. In our first analysis, we evaluated the cyto-
toxicity of the gold(I) metal-complexes MC2, MC3 and
MC4 in four pancreatic cancer cell lines, namely Bxpc3,
Miapaca2, Panc1 and ASPC1 using MTT assay. The free
ligand (MC1), 1,3-diethylbenz imidazolium iodide, and
the well-known chemotherapeutic drug gemcitabine
(Gem) were included as references [32]. The structures
were listed in Figure 1A. After 72 h treatment we ob-
served that Gem was sufficient to block 50% of cell
growth in Bxpc3 and Miapaca2 cells at 10 nM, whereas
IC50 values were more than 20 μM in Panc1 and ASPC1
(Figure 1B). In MC series, we could not detect any anti-
proliferative effect of the organic ligand (MC1) at 50 μM
in all of the four cell lines. By contrast, MC2, possessing a
chloride as leaving group, exhibited a good inhibitory ef-
fect with IC50 values of 12.05 ± 0.44, 2.44 ± 0.26, 7.01 ±
0.35 and 6.40 ± 0.32 μM in Bxpc3, Miapaca2, Panc1 and
ASPC1 respectively (Figure 1B), while MC4, carrying tri-
phenylphosphine instead of chloride, inhibited cell growth
Figure 1 IC50 values of gold(I) NHC complexes. (A) Structures of compounds. (B) IC50 values of compounds in Bxpc3, Miapaca2, Panc1 and
ASPC1, as well as HFF cells, at different times as indicated. The detailed procedure is described in the experimental section. The IC50 [μM] values
were calculated from dose–response curves in three independent experiments.
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and 0.77 ± 0.06 μM in the respective cell lines
(Figure 1B). Interestingly, the most potent compound
was MC3, substituted with a second benzimidazoly-
lidene moiety, whose IC50 values were 0.06 ± 0.01,
0.07 ± 0.02, 0.21 ± 0.02 and 0.28 ± 0.01 μM in corre-
sponding PDACs (Figure 1B). Additionally, we also
measured the short-term effect of MC3 and MC4 and
detected remarkable toxicity of MC3 and MC4 after
24 h and 48 h treatment in Panc1 and ASPC1 (Figure 1B).
Of note, MC3, MC4 and Gem exhibited low toxic
effects on human neonatal foreskin fibroblasts (HFF),
implicating they might preferentially kill cancer cells
(Figure 1B). The MTT assay is a colorimetric prolifera-
tion and cell viability assay, which is based on the meas-
urement of the activity of mitochondrial succinate
dehydrogenase [33]. Since mitochondria had been
shown to be a direct target of gold(I) NHC complexes
[9,10], we also used total protein quantification with
sulforhodamine B, known as SRB assay, to measure
cellular growth and proliferation [34]. The results ob-
tained were similar in both assays. Since Panc1 and
ASPC1 are resistant to Gem, we focused on these twocell lines, in particular Panc1, which possesses muta-
tions in p53, in our further experiments [35,36].
Cell cycle arrest, reduction of ROS formation and
induction of apoptosis upon MC3 treatment
To shed light on the mechanism of cell death we stained
treated cells with FITC-conjugated annexin v, which binds
to phosphatidylserine translocated to the outer cell mem-
brane layer during apoptosis [37,38], and propidium iodide
(PI), which is only taken up after membrane damage, to
distinguish necrotic cells. Panc1 cells were incubated with
increasing concentrations of MC3 for 24 and 48 hrs. After
treatment cells were counted and analyzed by FACS (fluor-
escence activated cell sorting). Treatment not only reduced
cell number, but also led to a concentration-dependent in-
crease in the population of annexin v positive cells com-
pared to DMF treatment as mock already after 24 h
(Figure 2A). The significance of apoptotic cell death is even
more clearly visible after 48 h treatment. Cell numbers are
further reduced and the relative amount of early apoptotic
and late apoptotic cells is increased in the remaining cell
population (Figure 2B). Analysis of cell cycle distribution in
intact cells after 24 h treatment, detected accumulation of
Figure 2 (See legend on next page.)
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Figure 2 MC3 induced cell apoptosis in Panc1. The cells were incubated with various concentrations of MC3 for 24 h (A) and 48 h (B), and
analyzed by FACS using annexin v/PI staining. (C) S and G2/M phase cell arrests occurred 24 h after treatment in Panc1. The relative DNA content
was analyzed by FACS using PI staining. The percentage of cells was determined by using trypan blue assay. (D) MC3 prevented colony formation
in Panc1. Panc1 cells were treated with increasing concentrations of MC3 for 24 h, re-plated at 2000 cells/well in a new 6-well plate and detected with
crystal violet after 3 weeks cultivation. (E) MC3 inhibited cell migration in wound healing assay. Panc1 cells were incubated with DMF as mock or MC3
(1.25 μM) under optimized condition as described in experimental section, and photos were taken at 0 h, 24 h and 48 h.
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companying cell cycle arrest. To investigate the ability of
cells to grow into a colony after treatment, we performed a
colony formation assay by seeding equal amount of cells,
pre-incubated with increasing concentrations of MC3 for
24 h. After 3 weeks of continuous cultivation, cells were
stained with crystal violet. Hardly any visible colony could
be found, when cells were treated with 5 μM or 10 μM
during pre-incubation (Figure 2D). We also performed a
wound healing assay, under conditions optimized for low
cell proliferation (0.5% serum) with an assay-specific opti-
mized concentration of MC3 (1.25 μM) to minimize tox-
icity. After 48 h incubation in this condition, we hardly saw
any cell able to enter the gap generated with a scratch in
the cell layer, indicating reduced cell mobility in presence
of MC3 (Figure 2E).
Since 5 μM of MC3 was sufficient to obtain a significant
amount of apoptotic cells after 24 h treatment (Figure 2A),
we decided to assess the formation of ROS in a time-
dependent study at this concentration. We used dihy-
droethidum (DHE) and FACS analysis for ROS detection.
ROS levels were clearly changed, showing a dramatic ele-
vation as early as 15 min (3-fold over mock) after treat-
ment started, with a maximum after 3 h (4.4-fold) and
3.9-fold (over mock) after 24 h (Figure 3A). The slight de-
crease at the later time point might be explained by an
increased compensation in cancer cells attempting to
overcome MC3-indcued excessive ROS for survival. We
further analyzed ROS formation at various concentrations
at 3 h and 24 h, both showing a concentration-dependent
increase (Figure 3B) in good agreement with previous
findings that MC3 acts as a potent TrxR inhibitor [9,10].
Since increase of ROS may be initiated from dysfunc-
tional mitochondria [39], we analyzed the mitochon-
drial membrane potential, with the cytofluorimetric,
lipophilic cationic dye, 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolyl-carbocyanine iodide (known
as JC-1) in Panc1 upon MC3 treatment [40]. We found a
constant decrease in the ratio of red to green fluorescence
indicating a decline in the mitochondrial membrane poten-
tial in MC3-treated cells (Figure 3C). In addition, Bcl-xl, an
anti-apoptotic protein, was concentration-dependently re-
duced after 24 h (Figure 3D). All above observations to-
gether provide a clear indication that MC3 is a small
molecule efficiently inhibiting cell proliferation by targeting
redox regulation in Panc-1 cells.Activation of the ASK1-p38-MAPK pathway in response
to MC3
Reduced Trx can bind to ASK1 and consequently blocks
ASK1 activity [22]. Therefore, we postulated that inhibition
of TrxR by MC3 might keep Trx in the oxidized state,
which could release free ASK1 and in turn activate the
p38-MAPK pathway to promote cell apoptosis. Using im-
munoblotting we clearly detected concentration-dependent
activation of phospho-p38-MAPK (T180/Y182) upon MC3
for 1 h (Figure 4A and Additional file 1: Figure S1). We
found a fast activation of p38-MAPK by MC3 (<30 min),
which persisted over the test period of 24 h (Figure 4B and
Additional file 1: Figure S2). We also observed phosphoryl-
ation of p53 and PARP cleavage after 24 h (Figure 4B and
Additional file 1: Figure S2), hallmarks of cell apoptosis,
in line with our above findings that MC3 induced cell
cycle arrest and apoptosis. Analysis of phosphorylated
p38-MAPK and HSP27 using quantitative phosphopro-
tein ELISA microarrays [41] confirmed time- (Figure 4C)
and concentration-dependent (Figure 4D) activation of
p38-MAPK signaling upon MC3 [42], while phosphoryl-
ation of other signal transduction kinases like Erk1/2,
Akt and GSK3ß was not significantly changed.
To further understand the profound role of the ASK1-
p38-MAPK cascade in the cellular response to MC3, we
isolated RNA after treatment with MC3 (5 μM) for 6 h
and analyzed expression of p38-MAPK downstream genes
including ATF2 [43], Stat1 [44] and TP53 [45]. Expression
of ATF2, Stat1 and TP53 was clearly induced upon MC3
treatment (Figure 4E), confirming the activation of p38-
MAPK signaling by MC3 in Panc1 cells. We further tested
if gold(I) NHC complexes could generally activate p38-
MAPK in Panc1 and ASPC1 cells and found abundant
phospho-p38-MAPK only in presence of MC3 or MC4
(Figure 4F and Additional file 1: Figure S3), implicating a
relationship between the anti-proliferative effect of gold(I)
NHC complexes and p38-MAPK activity.
p38 and ROS are involved in MC3-induced apoptosis
To confirm this mechanism on the molecular level, we next
used a chemical p38-MAPK inhibitor (p38i, SB203580) in a
co-treatment with 5 μM MC3 in Panc1 for 1 h. The results
obtained confirmed that this combination could not only
block MC3-induced activation of p38-MAPK-associated
proteins, such as p38-MAPK and ATF2, but also activation
of p53 (Figure 4G and Additional file 1: Figure S4),
Figure 3 (See legend on next page.)
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Figure 3 MC3 interfered cellular redox homeostasis. MC3 promoted ROS formation in time- (A) and concentration (B)-dependent manner. Panc1
cells were incubated with MC3 as indicated and ROS formation was measured using DHE. Data were normalized to the value of DMF-treated cells. (C)
MC3 reduced membrane potential. Panc1 cells were treated with MC3 5 μM at indicated time points and collected for the measurement as described
in the experimental section. The data show a clear reduction in the ratio of red population defined as R2 to green population defined as R3. DMF was
used as mock and CCCP (carbonyl cyanide 3-chlorophenylhydrazone) as the positive control. Data were normalized to the value of non-treated cells.
The raw data of mock and MC3 treatment for 3 h are depicted in an inset picture. (D) MC3 inhibited Bcl-xL activity. The amount of Bcl-xL was
determined by FACS using Alexa Flur® 488-conjugated Bcl-xL antibody in 24 h MC3-treated Panc1 cells. DMF was used as mock.
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volved in MC3-mediated cell death. Since MC3 is a
TrxR inhibitor, we next investigated if adding a ROS
scavenger could prohibit activation of the p38-MAPK
cascade. Two anti-oxidants, N-actetyl-L-cysteine (NAC,
10 mM) and reduced glutathione (Glu, 5 mM), were
used in co-incubation with MC3 (5 μM) for 1 h. Surpris-
ingly, both antioxidants could not alter the level of
phospho-p38-MAPK and -p53 (Figure 4G and Additional
file 1: Figure S4). Importantly, the higher level of ROS
(Figure 4H) and the lower mitochondrial membrane po-
tential (Figure 4I) compared to DMF control could still be
detected at this early time point (1 h) of MC3 treatment in
presence of NAC and Glu.
We further questioned if the p38 inhibitor (p38i) and
anti-oxidant treatment are able to prevent cells from
MC3-induced damage. Thus, we exposed Panc1 to MC3
in presence of ROS scavengers or p38i for 24 h and ana-
lyzed cell populations labeled with annexin v/PI as de-
scribed before. The results clearly showed that ROS
scavengers and p38i significantly counteracted the tox-
icity of MC3 (Figure 5A). Further immunoblotting data
demonstrated that PARP cleavage induced by MC3 dis-
appeared in co-treatment with p38i or ROS scavengers
after 24 h (Figure 5B, Figure 5C and Additional file 1:
Figure S5). We also, found that ROS scavengers consid-
erably reduced the activity of p38-MAPK (Figure 5C and
Additional file 1: Figure S5), as well as ROS accumula-
tion (Figure 5D) and cell cycle arrest (Figure 5E) after
24 h, indicating a compensatory effect of ROS scaven-
ging against MC3 in a long-term treatment. Interest-
ingly, p38i attenuated cellular apoptosis caused by MC3,
but enhanced ROS level (Figure 5D), suggesting that
cells under severe oxidative stress might employ p38-
MAPK to cope with excessive ROS.
MC3 disrupts ASK1-Trx interaction and ASK1-deficient
cells are resistant to MC3
Disruption of the interaction between ASK1 and Trx
can activate ASK1-p38-MAPK signaling [22,23]. To in-
vestigate whether activation of p38-MAPK was a result
of releasing ASK1 from Trx caused by blocking the re-
ductive recycling of Trx upon MC3, we used an ASK1
antibody to precipitate cellular ASK1 and examined the
level of Trx binding to ASK1. After 4 h MC3 treatmentthe level of Trx in complex with ASK1 was clearly re-
duced, while ASK1 and Trx levels were not changed in
the whole cell lysates (Figure 6A and Additional file 1:
Figure S6), demonstrating that MC3 suppressed ASK1
binding to Trx.
To further analyse the role of ASK1 in MC3-induced
apoptosis, we genetically reduced the level of ASK1
using siRNA in HeLa cells and detected lack of ASK1
resulting in the reduction of p38-MAPK activity without
changing total p38 levels in response to 5 μM of MC3
(Figure 6B and Additional file 1: Figure S7). We used
annexin v to label apoptotic cells after 24 h treatment
with MC3 at 5 μM in HeLa cells transfected with in-
creasing concentrations of ASK1 siRNA and observed a
clear rescue with 20 nM of ASK1 siRNA (Figure 6C).
We also transfected Panc1 with ASK1 siRNA (Figure 6D,
right and Additional file 1: Figure S8) and found a similar
reduction of MC3 toxicity (Figure 6E). However, a higher
amount of siRNA (50 nM) was required to achieve this ef-
fect (Figure 6D and Additional file 1: Figure S8). Finally,
we examined the influence of p38i, ROS scavengers and
ASK1 siRNA on the activity of MC3 in ASPC1 cells. Com-
parably to the results in Panc1, viability of ASPC1 cells
under MC3 treatment was markedly elevated in presence
of one of the inhibitors, including ASK1 siRNA, ROS scav-
enger (Glu and NAC) and p38i (Figure 6F).
Discussion
Pancreatic cancer, also known as pancreatic ductal adeno-
carcinoma, is one of the most incurable tumors with a rate
less than 5% of 5-year survival [31]. Gemcitabine (Gem) is
one of the FDA approved small molecules recommended
to treat pancreatic cancer in advanced and metastatic
stages with a modest, but statistically significant advantage
in survival versus 5-fluorouracil [32]. Nevertheless, many
pancreatic tumors like Panc1 are insensitive to Gem [46],
also confirmed with our assay at concentrations of up to
20 μM. By contrast, MC3 showed an approximately 100-
fold higher cytotoxicity in both pancreatic cancer cell lines
and low toxicity against the non-cancer cell line HFF, sug-
gesting a beneficial use of MC3 in gemcitabine resistant
pancreatic cancer.
MC3 is a gold(I) NHC complex recently reported by
our group and has been identified as a TrxR inhibitor
[9,10]. TrxR is required to convert oxidized Trx into its
Figure 4 (See legend on next page.)
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Figure 4 Role of P38-MAPK cascade in MC3-mediated cellular apoptosis. (A) MC3 activated p38-MAPK. Panc1 cells were incubated with
increasing concentrations of MC3 as indicated for 1 h. Whole cell lysates were subjected to immunoblot and probed with p38-MAPK and
phospho-p38-MAPK antibodies. DMF was used as mock, ß-Actin as loading control and 40 μg proteins were loaded per lane. (B) MC3 activated
p53 and induced PARP cleavage. Panc1 cells were treated with 5 μM MC3 as shown. Phospho-p53 and PARP cleavage were detected with
respective antibodies in immunoblot. Phosphorylation of p38-MAPK, HSP27, Erk1/2, GSK3ß and Akt were determined by microarray analysis in
concentration- (C) and time- (D) dependent studies. (E) MC3 activated expressions of p38-MAPK-related genes. Panc1 cells were incubated with
MC3 5 μM for 6 h and the expression of ATF2, TP53 and Stat1 were analyzed by qRT-PCR. Data were normalized to the value of DMF-treated cells,
shown is the mean ± SD of quadruplicates and representing three independent experiments. (F) p38-MAPK was activated by MC3 and MC4
treatment in ASPC1 and Panc1 cells. The cells were treated with gold(I) NHC complexes or ligand for 1 h. Phospho- and total-p38-MAPK were
detected with corresponding antibodies. (G) p38 inhibitor (p38i), but not ROS scavengers, blocked MC3-activated p38-MAPK pathway within 1 h
incubation. Panc1 cells were incubated with 5 μM MC3, 10 mM NAC, 10 μM p38i, 5 mM Glu or in combination as indicated for 1 h. Phosphorylation of
p38-MAPK, ATF2 and p53 were detected by using specific antibodies. ROS scavenger did not influence on MC3-caused ROS formation (H) or
mitochondrial membrane potential alternation (I). The densitometric analyses of corresponding immunoblots are provided in supporting information.
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consequently improves cell viability under oxidative stress
[14]. Our results demonstrated that MC3 blocks this
mechanism. As a results, the level of ROS was increased
and mitochondrial membrane potential was decreased in
Panc1 in response to MC3 treatment, whereas ROS scav-
engers reduced cell lethality (Figure 6G). Thus, the disrup-
tion in redox balance due to inhibition of TrxR should be
the main mechanisms of MC3 mediated cell death, and
explained by the following pathways.
Trx is a physiological inhibitor of ASK1 based on direct
interaction and thus termination of ASK1-p38-MAPK-
dependent apoptosis [22,23]. Given that this interaction
only occurs with Trx in its reduced form [24], MC3 logic-
ally reduced the binding of ASK1 to Trx as we showed in
Figure 6A. As a result, free released ASK1 led to phoshor-
ylation of p38-MAPK, which could be detected in all three
cell lines investigated, including Panc1, ASPC1 and HeLa
(wild type). In ASK1-deficient cells, p38-MAPK remained
mostly in its inactive form, confirming that ASK1 is re-
quired for p38-MAPK activation upon MC3 treatment
(Figure 6G).
p38-MAPK is a member of the mitogen-activated pro-
tein kinases family [47]. In comparison to other members,
namely Erk1/2-MAPK and JNK-MAPK, which are often
activated in human tumors and associated with cell prolif-
eration, migration and metastasis, p38-MAPK had been
described as a tumor suppressor, in particular under stress
conditions [48]. The p38-MAPK pathway can be regulated
by transcriptional and post-transcriptional mechanisms to
influence cell death signaling and pro- and anti-apoptotic
Bcl-2 proteins [47]. Cells with suppressed p38-MAPK sig-
naling either using ASK1 siRNA or chemical p38 inhibitor
were resistant to MC3 in Panc1, ASPC1 and HeLa cells,
supporting the major role of the ASK1-p38-MAPK signal-
ing axis in the induction of cell death by this gold(I) com-
plex (Figure 6G). MC3-treated cells underwent G2/M
arrest, showing constantly phosphorylated p53 and de-
creased Bcl-xL levels. Inhibition of p38 blocked phosphor-
ylation of p53 and increased cell survival. Our results arein good agreement with previous findings, showing that
p38 can regulate cell death through phosphorylation of
p53, which leads to p53 stabilization and triggers cell cycle
arrest in the G2/M phase [49].
Conclusions
Taken together, the balance between intracellular ROS and
redox capacity is crucial for maintaining cellular homeosta-
sis and plays an imminent role in the capacity of cancer
cells to cope with the oxidative stress associated with in-
creased metabolic activity of rapidly growing cells found
particularly in advanced stage tumors. Treatment with gold
(I) NHC complexes interferes with this balance and leads
to activation of the ASK1-p38-MAPK cascade and in con-
sequence triggers apoptosis in gemcitabine-resistant pan-
creatic cancer cells. This very specific active profile of a
gold(I) NHC complex indicates an interesting potential




thylbenzimidazol- 2-ylidene)gold(I) (MC2), [di-(1,3-diet
hylbenzylimidazol-2-ylidene)]gold(I) iodide (MC3), [tri-
phenylphosphine-1,3-diethylbenzylimidazol-2-ylidene)]gold
(I) iodide (MC4) were synthesized as described [9,10].
Structures and purities were ascertained by 13C- and 1H-
NMR, and mass spectroscopy and elemental analyses. N-
acetyl-L-cysteine (NAC), glutathione (Glu), gemcitabine
(Gem) and p38 inhibitor (p38i, SB203580) were purchased
by Sigma-Aldrich (Germany). p38 (cat: #9212), pp38
(T180/Y182, cat: #9215), PARP (cat: #9542), pp53 (S15, cat:
#9284) and pATF2 (T71, cat: #5112) were obtained from
cell signaling (NEB, Germany). ASK1 (cat: sc-7931) and
Trx (cat: sc-20146) were from Santa Cruz (Germany).
Cell culture
HeLa, Miapaca, Panc1 and HFF cells were cultured in
DMEM, and ASPC1 and BxPC3 in RPMI1640 containing
10% FBS and 1% Pen/Strp [32] under 5% CO2 at 37°C in a
Figure 5 Opposite effects of ROS scavenger and p38i against MC3. (A) ROS scavengers and p38i rescued MC3-induced cell apoptosis in
24 h treatment. Panc1 cells were incubated with 5 μM MC3, 10 μM p38i, 10 mM NAC or 5 mM Glu or in combination as indicated. The cell apoptosis
was analyzed by using annexin v/PI staining. Immunoblots showing: (B) p38i prevented PARP cleavage caused by MC3; and (C) reduced phospho-p38
levels and inhibition of PARP cleavage after co-treatment with ROS scavengers. Panc1 cells were incubated with inhibitors or MC3 or in combination
for 24 h as indicated. Vinculin was used as loading control. (D) Alternation of ROS production in combination of MC3 with inhibitors. ROS formation
was analyzed by FACS in Panc1 cells treated with various compounds or compounds combination for 24 h. The mean values were listed. (E) Glu
compensated MC3-mediated cell cycle arrest after 24 h treatment. The densitometric analyses of corresponding immunoblots are provided in
supporting information.
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dicated in the text. For depletion of ASK1, siRNA oligonu-
leotides were designed and synthesized by Riboxx (Riboxx
GmbH, Radebeul, Germany), based on the gene with
number NM_005923.3 and used for transfection of cells.
Sequences are: ASK1a: AUUUAGAUGAAAUACAGG(guide) and CCUGUAUUUCAUCUAAAU (passenger);
ASK1b: AUAUUAUCUACUCGCUG (guide) and GCA
GCGAGUAGAUAAUAU (passenger); ASK1c: AUUU
AAAAUACUCACU (guide) and GAGUGAGUAUUUC
UAAAU (passenger); ASK1d: UUCAAUGAUUGUAC
AG (guide) and GCUGUACAAUCUUGAA (passenger).
Figure 6 (See legend on next page.)
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Figure 6 The role of ASK1 in MC3-mediated cellular apoptosis. (A) MC3 interrupted the binding between ASK1 and Trx. Panc1 cells were
incubated with 5 μM MC3 as indicated. The cells were collected for immunoblot detected by Trx and ASK1 antibodies and for immunoprecipitation
precipitated with ASK1 antibody and then immunoblotted with ASK1 and Trx antibodies. (B) ASK1 siRNA inhibited phophorylation of p38-MAPK. HeLa
cells were transfected with ASK1 siRNAs for 48 h. The cells were treated with 10 μM MC3 for 1 h and collected for immunoblot. No target siRNA was
used in the transfection as negative control. (C) Resistance to MC3 in ASK1-deficient HeLa cells. After 48 h transfection with ASK1 siRNAs HeLa cells
were incubated with 5 μM MC3 for 24 h and the apoptotic cells were analyzed by FACS staining with annexin v/PI. (D) 50 nM of ASK1 siRNA was
sufficient to knockdown endogenous ASK1 in ASPC1 (left) and Panc1 (right) after 48 h detected by immunoblotting. (E) ASK1 siRNA rescued MC3-induced
cell apoptosis in annexin v/PI assay in Panc1. (F) ROS scavengers, p38i and ASK1 siRNA attenuated cellular damage upon MC3 in ASPC1 after 24 h
treatment. (G) Schematic model of MC3 induced cell apoptosis in pancreas. The densitometric analyses of corresponding immunoblots are provided in
supporting information.
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Riboxx®FECT reagent (Riboxx, Radebeul, Germany) was
used to get maximal transfectional efficiency according to
the manufacturer’s instructions. After 48 h transfection in
10% FBS, cells were treated with compounds as indicated
in the text.
Sulforhodamine B assay (SRB assay) and (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assay (MTT assay)
Effects on cell growth were determined using the SRB
assay and MTT assay at an initial cell density of 5,000
cells/well in a 96-well plate as previously reported [9,50].
ROS formation assay
Panc1 cells were plated in 12-well plate at a density of
200,000 cells/well and cultivated in standard condition
for 24 h before cells were treated with compounds as de-
scribed in the text. Cells were collected by trypsinization
and centrifugation with 200 g (1500 rpm), and resus-
pended in FACS buffer (1% BSA in PBS) containing 5 μM
dihydroethidium (DHE, Sigma-Aldrich). After 15 min in-
cubation at room temperature in the dark cells were
washed with FACS buffer, and immediately analyzed using
a FACSCalibur flow-cytometer (Becton Dickinson) and
CellQuest Pro (BD) analysis software (FACS analysis). Ex-
citation and emission settings were 488 nm and 564–
606 nm (FL2 filter), respectively. One representative result
is presented from at least three-independent experiments
showing comparable results.
Apoptosis assay
Panc1 and ASPC1 cells were seeded at a density of
200,000 cells/well in a 12-well plate under standard condi-
tions and treated with chemicals as indicated in the text.
After 24 h incubation cells were trypsinized and collected
by centrifugation. The annexin v/PI staining assay (BD,
Germany) was used to analyze cell apoptosis according to
the manufacturer’s protocol. Briefly, the cells were re-
suspended in the binding buffer and stained with FITC-
conjugated annexin v for 15 min, followed by PI staining
for 5 min at room temperature. The cell suspension was
immediately analyzed by FACS. An aliquot of the re-suspended cells was used to determine the cell number
after treatment, using a hemacytometer and trypan blue.
The relative amount of cells was calculated as the number
of trypan blue negative cells divided by the number in the
mock treatment.
Cell cycle analysis
Panc1 cells were seeded at a density of 200,000 cells/well in
a 12-well plate under standard conditions. The cells were
treated as designed, trypsinized and collected as mentioned
above. The pellets were fixed in 70% Ethanol at least for
24 h, washed two times with ice-cold PBS and resuspended
in 500 μL PBS. Cell suspensions were incubated with
RNase A (50 μg/mL) for 30 min at 37°C and sequentially
stained with PI (50 μg/mL) for 1 h and analyzed by FACS.
At least two-independent experiments were performed.Detection of Bcl-xL by flow cytometry
Panc1 cells were cultivated under standard conditions
(200,000 cells/well in a 12-well plate) and treated with
various concentrations of MC3 as indicated for 24 h. After-
wards cells were trypsinized, collected, fixed in 4% parafor-
maldehyde for 10 min at 37°C and permeabilized in 90%
methanol for 30 min on ice. Cells were blocked with 0.5%
BSA solution in PBS, incubated with Alexa Flur ® 488-
conjugated Bcl-xL (cat: #2767, cell signaling, NEB) for 1 h
at RT, washed with PBS and analyzed by FACS. Excitation
and emission settings were 488 nm and 564–606 nm (FL2
filter), respectively.Mitochondrial membrane potential
Panc1 cells (200,000 cells/well in a 12-well plate) were
cultivated in DMEM with 10% FBS and treated with
compounds as indicated. Cells were then stained with
2.5 μM JC-1 (5,5,6,6-tetrachloro-1,1,3,3- tetraethylbenzi-
midazolylcarbocyanineiodide, Sigma-Aldrich) for 30 min
at 37°C, collected, and analyzed by FACS. Excitation and
emission settings were 488 nm, 515–545 nm (FL1 chan-
nel) for JC monomers, and 564–606 nm (FL2 channel)
for JC aggregates. Comparable results were obtained
from at least in two-independent experiments.
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Cell extracts were homogenized in urea-lysis buffer
(1 mM EDTA, 0.5% Triton X-100, 5 mM NaF, 6 M Urea,
1 mM Na3VO4, 10 μg/mL Pepstatin, 100 μM PMSF and
3 μg/mL Aprotinin in PBS). Enhanced chemilumines-
cence (ECL) immunoblot analysis was performed. For
this 40 μg of total protein was resolved on 10% SDS-
PAGE gels and immunoblotted with specific antibodies.
Primary antibodies were incubated at a 1:1,000 dilution
in TBS (pH 7.5) with 0.1% Tween-20 and 5% BSA/non-
fat milk with gentle agitation overnight at 4°C. The
proper secondary antibodies were incubated in TBS
(pH 7.5) with 5% BSA/nonfat milk and 0.1% Tween-20
at a 1:5,000 dilution for 1 h at room temperature. Com-
parable results were obtained from at least in two-
independent experiments.
Immunoprecipitation
Immunoprecipitation was performed according to
the manufacture’s protocol (Cell Signaling, Frankfurt,
Germany). Briefly, cells were lysed in lysis buffern
(100 mM TRIS/HCl pH 7.5, 150 mM NaCl, 1 mM
MgCl2, 0.25% NP-40, 5 mM NaF, 1 mM Na3VO4,
10 μg/mL Pepstatin, 100 μM PMSF and 3 μg/mL Apro-
tinin) and incubated with Rabbit serum (DAKO) for
1 h on ice and Agarose A/G-protein bead (Santa Cruz)
for 30 min. Supernatant was immunoprecipitated with
ASK1 (1:100, Santa Cruz) overnight at 4°C. Immune com-
plexes were precipitated with Agarose A/G-protein bead
for 2 h at 4°C min and analyzed by immunoblotting. Clean-
Blot IP Detection Reagent (Thermo) was used to reduce
background caused by denatured and blotted IgGs accord-
ing to manufacture’s protocol. Comparable results were ob-
tained in at least two-independent experiments.
qRT-PCR
Quantitative reverse-transcription real-time-PCR was
performed using a Light Cycler 480 (Roche, Germany)
following a reference protocol from the manufacturer.
Briefly, total RNA was isolated from cells using TRIzol
(Qiagen, Germany). cDNA was generated by reverse-
transcription using random primers and equivalent
quantities of RNA. qPCR was performed using the
SYBR Green PCR master mix (Roche, Germany) and
the following primer pairs (MWG, Eurofins, Germany):
ATF2 (5 s: CAGCGTTTTACCAACGAGGA; 3as: GA
ATCTTGTTGGTGTTGGGGTC); TP53 (5 s: CCTCAC
CATCATCACACTGGAAG; 3 s: CCTTTCTTGCGGAG
ATTCTCTTCC); Stat1 (5 s: GGAAAAGCAAGCGTAA
TCTTCAGG; 3as: GAATATTCCCCGACTGAGCC); and
Actin (5 s: CTGACTACCTCATGAAGATCCTC; 3as: CA
TTGCCAATGGTGATGACCTG) as internal control. Re-
sults were obtained in three-independent experiments. Pro-
grams: preincubation, 1 cycle, 95°C, 5 min; quantification,48 cycles, 95°C 10 sec, 60°C 10 sec, 72°C 20 sec; melting
curve, 95°C 5 sec, 65°C 15 sec; cooling, 40°C.
Wound healing assay
Panc1 cells were plated at high density (200,000 cells/
well) into 12-well plates and grown to confluence. The
scratch was made by a sterile P-200 micropipette in the
middle of each well. Cells were then washed three times
with PBS and treated with MC3. Photographs of the
same fields were taken at the beginning, after one day
and at the end of the experiments (2 days).
Colony formation assay
Panc1 cells were plated into 12-well plate and grown to
70% confluence. Then cells were treated with MC3 for
24 h, harvested and re-plated into six-well plates with
2,000 cells/well. Medium were changed every 5 days. After
3 weeks, cells were stained with a staining solution con-
taining 6% glutaraldehyde and 0.5% crystal violet for 1 h.
Protein microarray analysis
Phosphorylated proteins were quantified using sandwich
ELISA microarrays. The microarrays are based on the
ArrayStrip™ platform (Alere Technologies GmbH, Jena,
Germany). A detailed description of the assay protocol
and information on reagents for this assay have been pre-
viously reported [41].
Statistical analysis
Data were expressed as the mean ± SD of at least three
independent experiments. Statistical significance of com-
parisons was assessed using the Student’s t-test (Micro-
soft Excel) and one-way ANOVA analysis. P < 0.05 was
considered statistically significant.
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Additional file 1: Figure S1. Densitometric analysis of proteins in
Figure 4A. Figure S2. Densitometric analysis of proteins in Figure 4B.
Figure S3. Densitometric analysis of proteins in Figure 4F. Figure S4.
Densitometric analysis of proteins in Figure 4G. Figure S5. Densitometric
analysis of proteins in Figure 5C. Figure S6. Densitometric analysis of
proteins in Figure 6A. Figure S7. Densitometric analysis of proteins in
Figure 6B. Figure S8. Densitometric analysis of proteins in Figure 6D.
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